These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Effect of aldosterone and MR blockade on the brain and the kidney. Stier CT; Rocha R; Chander PN Heart Fail Rev; 2005 Jan; 10(1):53-62. PubMed ID: 15947892 [TBL] [Abstract][Full Text] [Related]
27. Renin-angiotensin-aldosterone system for blood pressure and electrolyte homeostasis and its involvement in hypertension, in congestive heart failure and in associated cardiovascular damage (myocardial infarction and stroke). Laragh JH J Hum Hypertens; 1995 Jun; 9(6):385-90. PubMed ID: 7473515 [TBL] [Abstract][Full Text] [Related]
28. Hypertension: renin-angiotensin-aldosterone system alterations. Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283 [TBL] [Abstract][Full Text] [Related]
29. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure. Adams KF Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S4-13. PubMed ID: 15160833 [TBL] [Abstract][Full Text] [Related]
30. Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity. Pérez-Rojas JM; Derive S; Blanco JA; Cruz C; Martínez de la Maza L; Gamba G; Bobadilla NA Am J Physiol Renal Physiol; 2005 Nov; 289(5):F1020-30. PubMed ID: 15998842 [TBL] [Abstract][Full Text] [Related]
31. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Struthers AD; MacDonald TM Cardiovasc Res; 2004 Mar; 61(4):663-70. PubMed ID: 14985063 [TBL] [Abstract][Full Text] [Related]
36. Aldosterone's mechanism of action: roles of lysine-specific demethylase 1, caveolin and striatin. Baudrand R; Pojoga LH; Romero JR; Williams GH Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):32-7. PubMed ID: 24275769 [TBL] [Abstract][Full Text] [Related]
37. Aldosterone: a risk factor for vascular disease. Fritsch Neves M; Schiffrin EL Curr Hypertens Rep; 2003 Feb; 5(1):59-65. PubMed ID: 12530937 [TBL] [Abstract][Full Text] [Related]
38. Pharmacological modulations of the renin-angiotensin-aldosterone system in human congestive heart failure: effects on peripheral vascular endothelial function. Nakamura M Curr Vasc Pharmacol; 2004 Jan; 2(1):65-70. PubMed ID: 15320834 [TBL] [Abstract][Full Text] [Related]
39. The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure. Hameedi A; Chadow HL Curr Hypertens Rep; 2000 Aug; 2(4):378-83. PubMed ID: 10981173 [TBL] [Abstract][Full Text] [Related]
40. [Significance of aldosterone antagonist therapy]. Christ M; Grimm W; Maisch B Internist (Berl); 2004 Mar; 45(3):347-54. PubMed ID: 14997312 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]